Immatics N.V.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| IMTX | BINV.ST | IMCR | HURA | JANX | ALLO | |
|---|---|---|---|---|---|---|
| Market cap | 1.05B | 240.84M | 1.51B | 109.61M | 1.11B | 411.13M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -3.4 | -0.9 | -37.7 | -2.8 | -6.9 | -1.9 |
| Price/book | 2.1 | 1.2 | 3.6 | 6.0 | 1.2 | 0.9 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −20.86% | −88.59% | −2.50% | −33.80% | −35.29% | +0.90% |
| Today | −2.33% | +2.09% | −2.66% | +3.93% | +2.02% | +6.25% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All IMTX news ›Immatics shows off its PRAME bispecific data at ESMO 2026
This is an encouraging signal, but it does not yet prove that IMA402 extends patients’ lives. The data come from an ongoing Phase 1b study without a control group. Moreover, follow-up for overall survival was still relatively short, at a…
Immatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 2026 ESMO Annual Meeting
Edible Garden Announces Commercial Supply Agreement and Strategic Partnership with Caney Fork Farms Robot Consulting Announces Receipt of Nasdaq Delisting Determination and Request to Appeal such Determination Before a Hearings Panel…
Reviewing Kura Oncology (NASDAQ:KURA) and Immatics (NASDAQ:IMTX)
Posted by Michael Walen on Oct 22nd, 2026 Immatics (NASDAQ:IMTX – Get Free Report) and Kura Oncology (NASDAQ:KURA – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two…
Contrasting Immatics (NASDAQ:IMTX) & Anixa Biosciences (NASDAQ:ANIX)
Immatics (NASDAQ:IMTX – Get Free Report) and Anixa Biosciences (NASDAQ:ANIX – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their…
Stifel initiates coverage of Immatics with Buy rating, $15 price target
Stifel initiated coverage on Immatics's stock with a rating of Buy and a price target of $15.00. The price target implies an upside of 119.6% from the Oct 13 close of $6.83. Positive Clinical Trial Outlook: Immatics is advancing its Phase…
Immatics N.V. (NASDAQ:IMTX) Stock Has Consensus Target Price of $20.60 According to Brokerages
View Our Latest Stock Report on Immatics Shares of IMTX stock opened at $7.43 on Friday. The firm has a market cap of $1.02 billion, a P/E ratio of -3.99 and a beta of 1.36. Immatics has a 1-year low of $7.02 and a 1-year high of $12.41.…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- defenseworld.net1
- marketbeat.com1
- themarketsdaily.com1
- tradingview.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 4 articles, not a forecast.